Skip to main content
Premium Trial:

Request an Annual Quote

Focus Diagnostics Licenses Evogen PCR Probe Technology

NEW YORK (GenomeWeb News) – Evogen has granted Focus Diagnostics a license to incorporate Evogen's HyBeacons PCR probe technology into Focus' molecular diagnostic products and services, the firms announced today.

HyBeacons probes are sequence-specific hybridization probes that contain two fluorophores per probe. Because HyBeacons are not hydrolyzed during PCR amplification, "positive confirmation of the amplicon is available by way of high definition melt curve analysis," according to the companies. They added that the technology provides "clear quantitative data" during amplification and has "proven capabilities with DNA and RNA targets."

Financial and other terms of the deal were not disclosed.

Evogen develops High Definition PCR molecular diagnostic systems and is based in Lenexa, Kan. Focus is a Quest Diagnostics business headquartered in Cypress, Calif., and develops molecular and immunology products, including the Simplexa line of molecular tests.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.